Yaw Bediako

Yaw Bediako

Yemaachi Biotech, Co-Founder and CEO

For decades, African genomes were a blind spot in global cancer research. Yaw Bediako is ensuring they become the blueprint for the cure. In 2025, Bediako’s Yemaachi Biotech, an Accra-based immunogenomics company focused on cancer research and precision medicine, moved beyond mere data collection to building an end-to-end ecosystem for African precision medicine.

In July, Yemaachi unveiled the NovaSeq X Plus, Illumina’s most powerful genome sequencer, in Ghana to accelerate research. In October 2025, Bediako orchestrated a landmark partnership with Bio Usawa to support pharmacogenomic research, designing monoclonal antibodies, and strengthening Africa’s scientific skills and infrastructure. That partnership bridges the gap between identifying African-specific cancer markers and actually producing the drugs to treat them on the continent. 

In 2025, Bediako focused on Yemaachi’s mission to build one of the most genetically diverse cancer databases globally, the African Cancer Atlas (TACA), launched in partnership with Roche, a Swiss multinational healthcare company, aimed at addressing the significant underrepresentation of African genomic data in global cancer research. 

TACA is now on track to sequence 15,000 genomes from 7,500 African cancer patients that will help identify new cancer biomarkers and address disparities in cancer outcomes.